摘要
目的观察自体外周血造血干细胞移植（APBSCT）治疗预后不良非霍奇金淋巴瘤（NHL）的疗效和安全性。方法2003年10月至2008年10月具有预后不良因素的NHL患者10例，经CY＋TBI方案预处理（其中2例双次APBSCT患者，第二次给予MEC方案）后行APBSCT治疗。结果12例次患者均获造血重建，中性粒细胞≥0．5×10^9／L的时间为7～14d，中位时间10．58d，血小板≥20×10^9／L的时间为10～37d，中位时间16．25d。移植后10例患者均完全缓解（CR），未见严重的不良反应，无移植相关死亡。随访至2009年3月31日，随访时间为3—65个月，中位随访时间为24个月，有7例无瘤生存至今，3例复发，其中1例因疾病进展死亡，另2例经治疗，目前仍带瘤生存。结论APBSCT是治疗预后不良NHL安全、简便、有效的方法。
Objective To observe the therapeutic effectiveness and safety of autologous peripheral blood stem cell transplantation （APBSCT） for poor-risk non-Hodgkin lymphoma （NHL）. Methods Ten patients with poor-prognosis NHL were enrolled from October 2003 to October 2008 in our institute. Ten patients were treated by APBSCT with CY＋TBI conditioning regimen （Two patients of them were treated by Double-APBSCT with MEC conditioning regimen）. Results Hematopoietic reconstitution was observed in all patients.The time of neutrophil count ≥0.5×10^9/L and platelet ≥20×10^9/L were at day 10 （range： 7-14） and day 16 （range： 10-37）, respectively. All patients achieved complete remission （CR） after transplantation. Severe toxicity and transplant related mortality were not observed. After a median follow-up of 24 （10-84） months,seven cases were in event-free survival and three cases relapsed. One of three relapsed patients died from progression of disease, the other was still alive after treatment. Conclusion APBSCT in the treatment of patients with poor-prognosis NHL is a safe, convenient and efficient treatment.
出处
《白血病．淋巴瘤》
CAS
2009年第10期606-608,共3页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
非霍奇金
外周血造血干细胞移植
移植
自体
预后
Lymphoma, non-Hodgkin
Peripheral blood stem cell transplantation
Transplantation, autologous
Prognosis
作者简介
通信作者：王志国，Email：wangzhiguo91006@163．com
